12:00 AM
Oct 15, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NAD(P) dependent steroid dehydrogenase-like (NSDHL); K-Ras (KRAS)



Cell culture and mouse studies suggest inhibiting NSDHL could help treat mutant KRAS-driven cancer. In a transgenic mouse fibroblast cell line expressing an...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >